Preclinical Research
BPC-157 increased tendon-cell outgrowth and migration in a laboratory study
Chang and colleagues tied the effect to tendon fibroblasts and a FAK–paxillin signal. The system is cells and experimental injury, not a rehabilitation protocol.
Mechanism papers are where BPC-157 stops being a list of healed rat tendons and becomes a claim about cells. Chang, Tsai, Lin, Hsu, and Pang, in the Journal of Applied Physiology, reported that the pentadecapeptide promoted tendon outgrowth, cell survival, and migration, and they implicated focal adhesion kinase and paxillin, proteins cells use when they move and anchor.
Why the pathway matters, and why it is not enough
A migration assay tells you the peptide can push tendon fibroblasts under the conditions of that dish or that animal model. It does not tell you the concentration a human tendon would see, how long the peptide remains intact after a subcutaneous injection, or whether faster migration in culture becomes stronger collagen in a person. FAK–paxillin signaling is also not unique to this peptide. Plenty of injury signals use the same machinery.
How this journal files it
This is preclinical mechanism, cross-referenced to the Achilles transection work rather than a replacement for it. Anyone summarizing Chang 2011 for a general audience should keep the words “tendon fibroblasts” and “experimental” in the first paragraph. The paper is linked above so the figures can be checked. There is no catalog recommendation attached, because a cell-migration result is not a purchasing argument.